An interview with Miyamoto Masashi (宮本昌志), President of Kyowa Kirin, has revealed the company's new medium-term management plan through 2025 and the next steps for Global Specialty Pharma (GSP). It outlines the company's long-term growth strategy and the specifics of how it will achieve GSP.
Kyowa Kirin's goal of becoming the Global Specialty Firm (GSP), which it has pursued since its establishment in 2008, is coming into view. The new medium-term management plan through 2025, announced on 4 February, offers a glimpse of GSP's next steps. The article explains the objectives of the new medium-term plan and the company's long-term growth strategy through an interview with President Miyamoto Masashi (宮本昌志).
The interview discusses the continuation of the growth strategy centred on achieving GSP and specific initiatives toward the next stage of growth. It indicates the outlook for the company's medium- to long-term plans and its policy of strengthening the provision of solutions to patients and customers.
Although the article is limited to paid members, the publicly available section presents GSP's next steps and the direction of its long-term strategy as the core points. It follows the key elements of Kyowa Kirin's growth roadmap through comments from President Miyamoto.